慢性乙型肝炎肝脏微循环障碍发生发展机制的研究

doi:10.3969/j.issn.1672-5069.2010.02.008

实用肝脏病杂志 ›› 2010, Vol. 13 ›› Issue (2): 104-106.doi: 10.3969/j.issn.1672-5069.2010.02.008

慢性乙型肝炎肝脏微循环障碍发生发展机制的研究

李志群, 张丰, 祝扬, 赵景民, 潘登, 杨建法, 赵雨来

100094 北京市解放军第261医院（李志群,张丰,祝扬）; 解放军第302医院病理科（赵景民,潘登,杨建法,赵雨来）

收稿日期:2009-12-01 出版日期:2010-04-10 发布日期:2016-04-18
作者简介:李志群女,39岁,医学博士,副主任医师。E-mail：fairydoctor168167@yahoo.com.cn15min

A study on the mechanism of intrahepatic microcirculation changes in patients with chronic hepatitis B and cirrhosis

LI Zhiqun, ZHANG Feng, ZHU Yang, et al.

261st Hospital,Beijing,100094

Received:2009-12-01 Online:2010-04-10 Published:2016-04-18

摘要/Abstract

摘要： 目的探讨慢性乙型肝炎患者肝脏微循环障碍的主要分子机制。方法选择不同纤维化分期CHB穿刺肝组织和肝硬化外科活检肝组织及健康肝移植供体肝组织,应用免疫组化EliVisionTM System法,检测肝组织中COX₁、COX₂、AngII、AT1及α-SMA蛋白表达情况,并分析它们与肝内小血管、微血管或肝窦病理改变的关系。结果在CHB肝组织内COX₁、COX₂、AngII、AT1、及α-SMA在血窦壁、肝内小的门静脉分支、肝动脉分支、中央静脉及小叶下静脉壁均呈不同程度的阳性表达,随肝纤维化程度的加重其表达水平明显升高,在活动期肝硬化肝组织内上述调节分子表达最强（x²=8.8535,P=0.0120）。结论肝纤维化和肝硬化程度与COX₁、COX₂等指标之间存在相关性。

关键词: 乙型肝炎, 肝硬化, 环氧合酶, 血管紧张素

Abstract: Objective To explore main molecular mechanism of introhepatic microcirculation obstruction induced by chronic hepatitis B virus. Methods The liver biopsy tissues from patients with chronic hepatitis B,cirrhosis and healthy control were obtained. α-smooth muscle actin（α-SMA）,cyclooxygenase2（COX₂）,COX₁,and angiotensinII in the fibrotic livers and cirrhosis were examined by using immunohistochemistry. Results α-SMA,COX₂,COX₁ and angiotensin II in hepatic sinusoidal wall,little portal venules branch,hepatic arteries branch,central vein,vein wall beneath lobules were positive. They were obviously up-regulated as compared to control. Conclusions Intrahepatic microcirculation changes was found in chronic hepatitis B and cirrhosis.

Key words: Liver cirrhosis, Hepatitis B, Cyclooxygenase, AngiotensinII

李志群, 张丰, 祝扬, 赵景民, 潘登, 杨建法, 赵雨来. 慢性乙型肝炎肝脏微循环障碍发生发展机制的研究[J]. 实用肝脏病杂志, 2010, 13(2): 104-106.

LI Zhiqun, ZHANG Feng, ZHU Yang, et al.. A study on the mechanism of intrahepatic microcirculation changes in patients with chronic hepatitis B and cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2010, 13(2): 104-106.

参考文献

[1] TOKAIRIN T,NISHIKAWA Y,WATANABE H, et al. Osteopontin expression in the liver with severe perisinusoidal fibrosis：autopsy case of Down syndrome with transient myeloproliferative disorder[J]. Pathol Int,2008,58（1）：64-68.
[2] ROCKEY DC. Hepatic blood flow regulation by stellate cells in normal and injured liver[J]. Semin Liver Dis,2001,21（3）：337-343.
[3] TIPOE GL,LIONG EC,CASEY CA,et al. A voluntary oral ethanol-feeding rat model associated with necroinflammatory liver injury[J]. 2008,32（4）：669-682.
[4] El-BASSIOUNY AE,ZOHEIRY MM,NOSSEIR MM,et al. Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma[J]. Med Gen Med,2007,9（3）：45.
[5] BREINIG M,SCHIRMACHER P,KERN MA. Cyclooxygenase-2（COX- 2 ）-a therapeutic target in liver cancer[J]. Curr Pharm Des,2007,13（32）：3305-3315.
[6] EIZAYAGA FX,AGUEJOUF O,DESPLAT V,et al. Modifications produced by selective inhibitors of cyclooxygenase and ultra low dose aspirin on platelet activity in portal hypertension[J]. World J Gastroenterol,2007,13（38）：5065-5070.
[7] PISTON D,WANG S,FENG Y,et al. The role of cyclooxygenase-2/prostanoid pathway in visceral pain induced liver stress response in rats[J]. Chin Med J （Engl）,2007,120（20）：1813-1819.
[8] HORRILLO R,PLANAGUMO A,GONZALEZ-PERIZ A,et al. Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor[J]. J Pharmacol Exp Ther,2007,323（3）：778-786.
[9] BATALLER R,GINES P,NICOLAS JM,et,al. Angioensin II induces contraction and proliferation of human hepaticstellatecells[J]. Gastroenterology,2000,118：1149-1156.
[10] 张晶,宗春华,李定国,等. 肝星形细胞存在局部肾素-血管紧张素-醛固酮系统[J]. 中华消化杂志,2003,21：38-40.

[1]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[2]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[3]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[4]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[5]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[6]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[7]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[8]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[9]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[10]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[11]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[12]	刘李, 杨烈, 陈海洋, 何承俊, 王建宇, 陈廷昊. 肝硬化门静脉高压症并发脾动脉盗血综合征患者脾切除联合贲门周围血管离断术后门脉血流动力学的变化^*[J]. 实用肝脏病杂志, 2019, 22(6): 884-887.
[13]	何志安, 余丽萍, 赖江琼, 黄思付. ARFI评估肝硬化并发食管胃底静脉曲张患者出血和门静脉血栓的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 888-891.
[14]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[15]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.

慢性乙型肝炎肝脏微循环障碍发生发展机制的研究

A study on the mechanism of intrahepatic microcirculation changes in patients with chronic hepatitis B and cirrhosis

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价